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of SVGs (FitzGibbon grade B) was observed. Of the 38 pa-
tients who underwent late graft evaluation, 24 did so at least
2 years after surgical intervention. The 2-year cumulative
patency rate was 91.7% (22/24). All the results were evalu-
ated by an experienced radiologist. Details of the occluded
SVGs are given in Table 2.
DISCUSSION
Stroke is a devastating complication of CABG.Manipula-
tion of the aorta using techniques such as crossclamping is
thought to be a predisposing risk factor. The off-pump tech-
nique has brought more attention to reduce this devastating
complication. Use of an aortic side clamp requires aortic
manipulation, thereby precluding the major advantage of
the off-pump technique. Several devices for proximal anas-
tomosis of SVGs to the aorta have been developed and can
facilitate clampless proximal anastomosis. Although the re-
sults have been satisfactory in terms of neurologic complica-
tions, there have been some concerns about early and long-
term patency rates. The early patency rate of the previous
generation of the proximal anastomosis device, the Symme-
try device (St Jude Medical, Inc, Minneapolis, Minn), was
satisfactory, but production was discontinued because of
the poor midterm and long-term results.3-5 The PAS-Port de-
vice has the potential to yield better results than the Symme-
try device for the following reasons: (1) the stents were
located outside and not inside the SVG, which did not reduce
the total amount of blood exposed to nonintimal surfaces in-
side the aortic lumen, and (2) the stents were composed of
316L medical grade stainless-steel and not nitinol, which
can cause intimal hyperplasia.1
We realize that the gold standard for the evaluation of
graft patency is angiography. It is relatively difficult to as-
sess the details of anastomosis sites with computed tomogra-
phy. Therefore we might have missed a number of stenotic
vessels. In addition, this is a very small cohort of patients.
In conclusion, this study demonstrated the satisfactory
results of midterm patency rate after placement of SVGs
with a PAS-Port device. This device could be useful for
CABG in case the ascending aorta showed the severe ather-
omatous change to a degree that precluded the use of a side
clamp. However, a larger-scale study and a longer follow-
up period will be mandatory to confirm the reliability of
this device.
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TABLE 2. Details of the occluded saphenous vein grafts
Preoperative
characteristics
Endoscopic
harvesting
Sequential
grafting
Target
coronary artery
Degree of
stenosis
Location of the
proximal anastomosis
73-year-old man Diabetes No No RCA 75% Ascending aorta
49-year-old man Dialysis, diabetes, CVD No No RCA 90% Ascending aorta
RCA, Right coronary artery; CVD, cerebrovascular disease.
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doi:10.1016/j.jtcvs.2008.02.053504 The Journal of Thoracic and Cardiovascular SurgMitral valve repair is the procedure of choice to correct mitral
regurgitation. The introduction of polytetrafluoroethylene
(PTFE) sutures was an important contribution by David1
and Zussa and colleagues2 for the treatment of chordal short-
ening or for chordal replacement during mitral valve repair.
This report describes a patient with acute-onset hematuria 11
years aftermitral valve repair whowas found to have fractured
PTFE neochordae necessitating mitral valve replacement.ery c February 2009
Brief CommunicationsCLINICAL SUMMARY
A 57-year-old man was transferred to our hospital with
acute onset of hemoglobinuria. A transesophageal echocar-
diogram revealed a mobile density attached to the mitral
leaflet with severe mitral regurgitation. His history was no-
table for a mitral valve repair in 1996 (11 years previously)
by one of the authors (L.H.C.), with PTFE neochordae cre-
ated for the anterior leaflet for myxomatous disease and the
placement of a 30-mmCosgrove-Edwards annuloplasty ring
(Edwards Lifesciences LLC, Irvine, Calif). The patient’s
myxomatous anterior leaflet had had six ruptured native
chordae that were resected, along with a portion of the ante-
rior leaflet. Two PTFE neochordae were then created from
the posteromedial and anterolateral papillary muscles in
mattress fashion, anchoring the chordae on the papillary
muscles with polytetrafluoroethylene pledgets. The patient
had been well for 11 years after that procedure, with no car-
diovascular symptoms since his initial mitral valve repair
and normal results of repeated echocardiograms.
Intraoperative transesophageal echocardiography re-
vealed a flail anterior leaflet with 4þ insufficiency (Figures
1 and 2). The mitral valve was approached through a full
sternotomy with ascending aortic cannulation, bicaval ve-
nous cannulation, and antegrade blood cardioplegia. The
Sonderga¨ard groove was developed to approach the left
atrium. Valve inspection revealed the two PTFE neochordae
in the anterior leaflet to be thickened, stiffened, and fractured
midshaft. The native anterior leaflet was diffusely myxoma-
tous, variably thickened, and fibrotic. The valve was irrepa-
rable, so the anterior mitral leaflet was resected and the
posterior leaflet preserved. The previous ring was removed,
and valve replacement was performed with a 27-mm St Jude
Medical bileaflet valve with an expanded PTFE cuff (St Jude
Medical Inc, Minneapolis, Minn). The patient did well and
FIGURE 1. Real-time 3-dimensional transesophageal echocardiographic
en face image of mitral valve from left atrial perspective showing original
Cosgrove-Edwards annuloplasty ring (white arrows) and flail anterior leaf-
let (red arrow). PMC, Posteromedial commissure; ALC, anterolateral com-
missure.The Journal of Thoracic andwas discharged home on postoperative day 5 with anticoa-
gulation.
DISCUSSION
PTFE neochordae have been used for a variety of mitral
reconstructive procedures. They were introduced and evalu-
ated experimentally in sheep and shortly thereafter intro-
duced by David1 and Zussa and colleagues2 for patients
undergoing mitral valve surgery. PTFE neochordae have
since been used in minimally invasive procedures and the
pediatric population.
To date, there has been only a single published report, by
Butany and associates in 2004,3 of a PTFE neochordal frac-
ture in a patient with mitral neochordae constructed for
anterior leaflet pathology in a rheumatic valve. This fracture
was noted at reoperation, 14 years after the initial repair. Bu-
tany and associates3 postulated that calcification of the PTFE
suture had led to fracture, and the patient’s valve was re-
placed as in our case. Similarly, the PTFE suture was calci-
fied and had been degraded.
Although it is known to be extremely durable, the natural
history of PTFE suture has not been completely elucidated.
PTFE has a greater than 50% porosity. As a linear, nonab-
sorbent, monofilament polymer, it has a breaking strength
almost an order of magnitude greater than that of native
chordae (1 kg vs 60–200 mg, respectively). There is some
compliance in the suture. It has an electronegative charge,
similar to native endothelium. Although thought to repel
hematocytes and tissue incorporation initially, eventually it
is covered by host fibrosa and endothelium. Finally, calcium
has been noted to penetrate the interstices with possible stiff-
ening.3 This gives neochordae the potential for calcification,
with the potential for eventual fracture.
FIGURE 2. Real-time 3-dimensional transesophageal echocardiographic
image of mitral valve apparatus from left ventricular perspective showing
fractured neochordae (red arrow). LVOT, Left ventricular outflow tract;
PL, posterior mitral valve leaflet; AL, anterior mitral valve leaflet.Cardiovascular Surgery c Volume 137, Number 2 505
Brief CommunicationsSeveral investigators have documented durability of
PTFE neochordae in the midterm (<10 years). David and co-
workers4 have shown no PTFE fractures in 134 patients at 8
years, and Kobayashi and associates5 have shown no PTFE
failures in 74 patients at 10 years. Even in children, who
have a tendency toward quite rapid calcification of biopros-
thetic valves, no fractures have been reported. Stiffening of
the PTFE chord has the potential to result in mitral valve in-
sufficiency. Althoughmidterm durability has been excellent,
the long-term (>10 y) outcome remains unreported.
Our patient had hemolytic anemia and hemoglobinuria,
well-recognized complications of mitral valve surgery that
are rare after mitral valve repair. This is the first report of506 The Journal of Thoracic and Cardiovascular Surfractured chordae leading to hemolysis and hematuria as a re-
sult of whiplash motion of the chordae and trauma on the pa-
tient’s red blood cells.
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